Allogeneic Vsts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data...

Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma GlobeNewswire June 16, 2023 78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data encouraging with no graft-versus-host-disease and no neurotoxicityUpdated data highlighted in podium presentation at the 17th...

Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa's "off the shelf" CD30.CAR

Investegate announcements from Tessa Therapeutics Ltd, Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)

Investegate announcements from Tessa Therapeutics Ltd, Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform